its inherent resistance to platinum-based chemotherapy. 4 – 6 In contrast, stage IA, IB, or IC disease solely caused by capsular rupture has been found to confer excellent prognosis, and therefore the benefit of adjuvant therapy is questionable. 1 , 6
Search Results
Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy
Soumyajit Roy, Paul Hoskins, Anna Tinker, Harinder Brar, Gale Bowering, and Gaurav Bahl
Decreasing Use of Chemotherapy in Older Patients With Stage III Colon Cancer Irrespective of Comorbidities
Viola Walter, Daniel Boakye, Janick Weberpals, Lina Jansen, Walter E. Haefeli, Uwe M. Martens, Phillip Knebel, Jenny Chang-Claude, Michael Hoffmeister, and Hermann Brenner
reasons for nonadherence to recommended adjuvant therapy in elderly patients whose health and preferences would allow for treatment. Acknowledgments The authors wish to thank Ute Handte-Daub, Ansgar Brandhorst, and Petra Bächer for their excellent
The Emerging Use of IMRT for Treatment of Cervical Cancer
Christopher Loiselle and Wui-Jin Koh
. 35 Cervical cancer clinical trials continue to use IMRT. The RTOG 0724 trial evaluating adjuvant therapy for lymph node–positive cervical cancer and Gynecologic Oncology Group (GOG) 263 for lymph node–negative cervical cancer allow IMRT, again
Operative Techniques in Early-Stage Lung Cancer
Thomas A. D'Amico
ratio, 4.9; P = .002). Administration of Adjuvant Chemotherapy One of the most promising advantages associated with thoracoscopic lobectomy relates to the ability of patients to tolerate adjuvant therapy. A recent study compared the ability to
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
Subsequently, in an interim analysis, an improvement in DFS—a secondary end point of the trial—was reported. 65 However, unlike the bisphosphonates, which have demonstrated an OS benefit when used as adjuvant therapy, no available data show an OS benefit with
Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow
surgery immediately before administration of adjuvant therapy, and for surveillance (category 2B) if the level is abnormally elevated at diagnosis. Systemic Therapy Approaches for Locally Advanced or Metastatic Disease Gemcitabine Monotherapy
Central Nervous System Cancers
Steven S. Brem, Philip J. Bierman, Henry Brem, Nicholas Butowski, Marc C. Chamberlain, Ennio A. Chiocca, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Deneen Hesser, Larry Junck, Gerald P. Linette, Jay S. Loeffler, Moshe H. Maor, Madison Michael, Paul L. Moots, Tara Morrison, Maciej Mrugala, Louis Burt Nabors, Herbert B. Newton, Jana Portnow, Jeffrey J. Raizer, Lawrence Recht, Dennis C. Shrieve, Allen K. Sills Jr, Frank D. Vrionis, and Patrick Y. Wen
Therapy: Fractionated EBRT after surgery is standard adjuvant therapy for patients with high-grade astrocytomas. Use of radiation is based on 2 randomized trials conducted in the 1970s, which showed increased survival. Walker et al. 15 compared
Bladder Cancer
Peter E. Clark, Neeraj Agarwal, Matthew C. Biagioli, Mario A. Eisenberger, Richard E. Greenberg, Harry W. Herr, Brant A. Inman, Deborah A. Kuban, Timothy M. Kuzel, Subodh M. Lele, Jeff Michalski, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Jerome P. Richie, Wade J. Sexton, William U. Shipley, Eric J. Small, Philippe E. Spiess, Donald L. Trump, Geoffrey Wile, Timothy G. Wilson, Mary Dwyer, and Maria Ho
. Cystectomy is rarely considered for a Ta, low-grade lesion. Intravesical Therapy Intravesical therapy is used in 2 general settings: as prophylactic or adjuvant therapy after a complete endoscopic resection or, rarely, as therapy with the goal of
Non–Small Cell Lung Cancer, Version 1.2015
David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
therapy for metastatic disease are not provided in this discussion, because the focus is on RT (see “Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy” and “Systemic Therapy for Advanced or Metastatic Disease” online, in these guidelines, at NCCN
NCCN Task Force Report: Bone Health and Cancer Care
Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak
conjunction with adjuvant therapy for breast cancer as an antiemetic or premedication for taxane therapy and may cause secondary osteoporosis. Radiation therapy can have a direct local effect on bone; for example, chest irradiation and pelvic irradiation are
